CAPR - Capricor Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.7200
+0.0200 (+0.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.7000
Open2.7200
Bid2.6600 x 1100
Ask2.7200 x 900
Day's Range2.6000 - 2.7800
52 Week Range2.3000 - 11.9000
Volume19,134
Avg. Volume779,682
Market Cap10.57M
Beta (3Y Monthly)3.68
PE Ratio (TTM)N/A
EPS (TTM)-3.7360
Earnings DateNov 11, 2019 - Nov 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.40
Trade prices are not sourced from all markets
  • Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring
    Zacks

    Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring

    Baxter (BAX) expects this deal to remain neutral to its earnings in 2019 and 2020.

  • GlobeNewswire

    Capricor Therapeutics to Present at Upcoming Conferences

    LOS ANGELES, Sept. 06, 2019 -- Capricor Therapeutics (NASDAQ: CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological.

  • Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety
    Zacks

    Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety

    Neogen's (NEOG) proprietary testing platform gets upgraded to reduce the incidence of bacterial contamination in livestock.

  • NuVasive's New TLIF Implant Broadens Spine Surgery Option
    Zacks

    NuVasive's New TLIF Implant Broadens Spine Surgery Option

    NuVasive's (NUVA) Modulus TLIF-A is designed to work smoothly with the existing MAS TLIF and MAS Midline access systems.

  • Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod
    Zacks

    Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod

    Boston Scientific's (BSX) Vercise Gevia DBS system should boost neuromodulation revenues for the company.

  • Here's What We Think About Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Pay
    Simply Wall St.

    Here's What We Think About Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Pay

    Linda Marbán became the CEO of Capricor Therapeutics, Inc. (NASDAQ:CAPR) in 2010. This report will, first, examine the...

  • Capricor Therapeutics (CAPR) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Capricor Therapeutics (CAPR) Reports Q2 Loss, Tops Revenue Estimates

    Capricor (CAPR) delivered earnings and revenue surprises of 26.25% and 86.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Capricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    Positive Results from HOPE-2 Interim Analysis Reported in July To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 06, 2019 -- Capricor Therapeutics.

  • Will Capricor Therapeutics (CAPR) Report Negative Q2 Earnings? What You Should Know
    Zacks

    Will Capricor Therapeutics (CAPR) Report Negative Q2 Earnings? What You Should Know

    Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Capricor Therapeutics to Present Second Quarter 2019 Financial Results and Recent Corporate Update on August 6

    Capricor Therapeutics (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its second quarter of 2019 financial results and corporate update shortly after the NASDAQ market close on Tuesday, August 6. Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.

  • GlobeNewswire

    Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy

    Capricor Therapeutics, Inc. (CAPR), a clinical-stage biotechnology company, today announced that its independent Data and Safety Monitoring Board (DSMB) completed its safety assessment and futility analysis review of the company’s ongoing Phase II HOPE-2 study with CAP-1002 in boys and young men who are in advanced stages of Duchenne muscular dystrophy (DMD) and recommended that the trial continue. “We are pleased with the DSMB's recommendation to continue the HOPE-2 clinical trial and supports our understanding of the safety of CAP-1002 in the DMD patient population, which is an important step toward establishing a potential new treatment to help these boys.

  • GlobeNewswire

    Capricor Therapeutics and Parents Project Muscular Dystrophy to Host Webinar to Discuss Interim Analysis of the HOPE-2 Clinical Trial to Treat Patients with Duchenne Muscular Dystrophy

    The public is invited to join Parent Project Muscular Dystrophy Founding President and CEO Pat Furlong and Capricor Therapeutics CEO Linda Marbán, Ph.D., at 1 p.m. ET on Wednesday, July 17, to discuss updates on Capricor's HOPE-2 clinical program.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For July 16, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Capricor Therapeutics, Inc.  (NASDAQ: CAPR ...

  • Capricor Therapeutics News: Why CAPR Stock Is Skyrocketing Today
    InvestorPlace

    Capricor Therapeutics News: Why CAPR Stock Is Skyrocketing Today

    Capricor Therapeutics news about the results from a recent clinical trial has CAPR stock soaring Monday.The positive results for Capricor Therapeutics (NASDAQ:CAPR) come from its Phase II clinical trial of CAP-1002. The study was seeking to determine the effectiveness of using the CAP-1002 investigational therapy in treating boys and young men treated with steroids that suffer from advanced stages of Duchenne muscular dystrophy.The study measures the results of the treatment in three categories, Skeletal, Pulmonary and Cardiac. What it found is that there was statistical improvement in all of these categories for patients that were were not in the placebo group.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe study included a total of 17 patients. Seven of these were treated with CAP-1002 and the other 10 were in the placebo group. Sever adverse events in the study saw two patients having a negative reaction to the treatment in late 2018. However, this was not a lasting issue. * 7 Dependable Dividend Stocks to Buy Linda Marban, President and CEO of the company, has this to say in the Capricor Therapeutics new release including the study results."We are extremely pleased and it is truly extraordinary that even in such as small sample size, we achieved statistically significant improvements in several clinically relevant parameters. In these older patients, functional improvement in the upper limb is highly meaningful for their quality of life. To our knowledge, this is the first randomized double-blind, placebo-controlled study in DMD that has shown statistically significant functional improvement in steroid treated boys."CAPR stock was up 151% as of Monday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dependable Dividend Stocks to Buy * 10 Stocks Driving the Market to All-Time Highs (And Why) * 7 Short Squeeze Stocks With Big Upside Potential As of this writing, William White did not hold a position in any of the aforementioned securities.The post Capricor Therapeutics News: Why CAPR Stock Is Skyrocketing Today appeared first on InvestorPlace.

  • MarketWatch

    Capicor Therapeutics' stock rockets on heavy volume after positive MD trial results

    Shares of Capricor Therapeutics Inc. nearly doubled (up 93%) in very active premarket trading Monday, after the biotechnology company announced upbeat results from a trial for its treatment (CAP-1002) of Duchenne muscular dystrophy. Trading volume was about 1.7 million shares ahead of the open, compared with the full-day average of about 56,500 shares. "I am incredibly pleased with the outcome of the interim analysis as it has demonstrated the biologic activity of CAP-1002 that has resulted in changes of clinically relevant outcomes including the upper limb, the hand and diaphragmatic function," said Craig McDonald, the principal investigator for the trial. The stock has lost 42.6% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF has slipped 4.5% and the S&P 500 has gained 3.7%.

  • GlobeNewswire

    Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy

    Capricor Therapeutics, Inc. (CAPR), a clinical-stage biotechnology company, today announced that a pre-specified interim analysis performed on 6-month data from the HOPE-2 trial showed statistically significant results across several independent clinical measures. “I am incredibly pleased with the outcome of the interim analysis as it has demonstrated the biologic activity of CAP-1002 that has resulted in changes of clinically relevant outcomes including the upper limb, the hand and diaphragmatic function,” said Craig McDonald, M.D., the national principal investigator for the HOPE-2 clinical trial and UC Davis professor and chair of its Department of Physical Medicine and Rehabilitation. HOPE-2 is a randomized, double-blind, placebo-controlled, Phase II clinical trial of the company’s lead investigational therapy, CAP-1002 in steroid-treated boys and young men who are in advanced stages of Duchenne muscular dystrophy (DMD), a debilitating genetic disorder.

  • What Kind Of Shareholders Own Capricor Therapeutics, Inc. (NASDAQ:CAPR)?
    Simply Wall St.

    What Kind Of Shareholders Own Capricor Therapeutics, Inc. (NASDAQ:CAPR)?

    Every investor in Capricor Therapeutics, Inc. (NASDAQ:CAPR) should be aware of the most powerful shareholder groups...

  • Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates
    Zacks

    Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates

    Capricor (CAPR) delivered earnings and revenue surprises of 27.27% and -42.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Capricor: 1Q Earnings Snapshot

    The Beverly Hills, California-based company said it had a loss of 8 cents per share. The biotechnology company posted revenue of $230,500 in the period. Its adjusted revenue was $231,000. In the final ...

  • GlobeNewswire

    Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

    On Track to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 13, 2019 -- Capricor.

  • ACCESSWIRE

    Capricor Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 13, 2019 / Capricor Therapeutics, Inc. (NASDAQ: CAPR ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 13, 2019 at 4:30 ...

  • GlobeNewswire

    Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13

    Capricor Therapeutics (CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its first quarter of 2019 financial results and corporate update shortly after the NASDAQ market close on Monday, May 13. Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.

  • Will Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Earnings Grow In The Years Ahead?
    Simply Wall St.

    Will Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Earnings Grow In The Years Ahead?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The most recent earnings announcement Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) released in December 2018 revealed...

  • Associated Press

    Capricor: 4Q Earnings Snapshot

    On a per-share basis, the Beverly Hills, California-based company said it had a loss of 11 cents. The biotechnology company posted revenue of $648,100 in the period. Its adjusted revenue was $648,000. ...

  • GlobeNewswire

    Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

    Plan to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, March 28, 2019 -- Capricor.